Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing
Jennifer Swainson, Larry J. Klassen, Stefan Brennan, et al.
CNS Drugs (2022) Vol. 36, Iss. 3, pp. 239-251
Open Access | Times Cited: 25

Showing 25 citing articles:

The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T. Le, Isabel Pazos Cordero, Muhammad Youshay Jawad, et al.
Journal of Psychiatric Research (2022) Vol. 151, pp. 476-496
Closed Access | Times Cited: 45
Roles of microglia in adult hippocampal neurogenesis in depression and their therapeutics
Shaoyi Fang, Zhibin Wu, Yali Guo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 30
Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada
Carson Chrenek, Bryan Duong, Atul Khullar, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 6
At-home, telehealth-supported ketamine treatment for depression: Findings from longitudinal, machine learning and symptom network analysis of real-world data
David S. Mathai, Thomas D. Hull, Leonardo Vando, et al.
Journal of Affective Disorders (2024) Vol. 361, pp. 198-208
Open Access | Times Cited: 6
Is there a risk of esketamine misuse in clinical practice?
Carlos Roncero, M. Merizalde Torres, Néstor Szerman, et al.
Therapeutic Advances in Drug Safety (2025) Vol. 16
Open Access
Ketamine for mental health - A naturalistic inventory of prescribing practices, safety, and adverse effects
Marta Stuart, Ian Stefanuk, Rebecca Comeau, et al.
PLOS mental health. (2025) Vol. 2, Iss. 4, pp. e0000215-e0000215
Open Access
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Maxwell Zachary Price, Richard L. Price
Biomarkers in Neuropsychiatry (2024) Vol. 11, pp. 100104-100104
Open Access | Times Cited: 4
Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand
Alistair Carroll, Adam Bayes, Mark Montebello, et al.
Australian & New Zealand Journal of Psychiatry (2024)
Closed Access | Times Cited: 3
Ketamine and Zinc: Treatment of Anorexia Nervosa Via Dual NMDA Receptor Modulation
Jules Mitchell, Daniel F. Hermens, Maxwell R. Bennett, et al.
CNS Drugs (2023) Vol. 37, Iss. 2, pp. 159-180
Open Access | Times Cited: 7
Does It Matter Whether a Psychiatric Intervention Is “Palliative”?
Brent M. Kious, Ryan H. Nelson
The AMA Journal of Ethic (2023) Vol. 25, Iss. 9, pp. E655-660
Open Access | Times Cited: 7
IV low dose ketamine infusions for treatment resistant depression: Results from a five-year study at a free public clinic in an academic hospital
Gilmar Gutiérrez, Melody J.Y. Kang, Gustavo Vázquez
Psychiatry Research (2024) Vol. 335, pp. 115865-115865
Open Access | Times Cited: 2
Guidelines for ketamine use in clinical psychiatry practice
Luke A. Jelen, Rupert McShane, Allan H. Young
BJPsych Open (2024) Vol. 10, Iss. 3
Open Access | Times Cited: 2
IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression
Gilmar Gutiérrez, Jennifer Swainson, Nisha Ravindran, et al.
Psychiatry Research (2024) Vol. 340, pp. 116125-116125
Open Access | Times Cited: 2
Learning how to make use of dissociative therapies
David S. Mathai
International Review of Psychiatry (2024), pp. 1-13
Closed Access | Times Cited: 2
Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory/inhibitory synaptic activity
Thi Mai Loan Nguyen, Céline Defaix, Indira Mendez‐David, et al.
Neuropharmacology (2022) Vol. 225, pp. 109357-109357
Open Access | Times Cited: 9
Oral ketamine may offer a solution to the ketamine conundrum
Megan Dutton, Adem Can, Jim Lagopoulos, et al.
Psychopharmacology (2023) Vol. 240, Iss. 12, pp. 2483-2497
Open Access | Times Cited: 5
A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential
Brittany Chubbs, Jay Ching-Chieh Wang, Shaina Archer, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 8
Beyond therapeutic potential: a systematic investigation of ketamine misuse in patients with depressive disorders
Keshav Juneja, Sabah Afroze, Zeel Goti, et al.
Discover Mental Health (2024) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Psychedelika und Dissoziativa in der Psychiatrie: Herausforderungen in der Behandlung
Johannes Jungwirth, Francesco Bavato, Boris B. Quednow
Der Nervenarzt (2024) Vol. 95, Iss. 9, pp. 803-810
Open Access | Times Cited: 1
Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand
Ben Beaglehole, Paul Glue, Mike Clarke, et al.
BJPsych Open (2023) Vol. 9, Iss. 6
Open Access | Times Cited: 3
Ketamine in psychiatry
Grace Pham, Sanjay J. Mathew
Elsevier eBooks (2024), pp. 339-356
Closed Access
Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the community
Ben Beaglehole, Richard Porter, Katie M. Douglas, et al.
BMJ Open (2024) Vol. 14, Iss. 5, pp. e084844-e084844
Open Access
Non-additivity of the functional properties of individual P450 species and its manifestation in the effects of alcohol consumption on the metabolism of ketamine and amitriptyline
Kannapiran Ponraj, Kari A. Gaither, Dilip Kumar Singh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Non-additivity of the functional properties of individual P450 species and its manifestation in the effects of alcohol consumption on the metabolism of ketamine and amitriptyline
Kannapiran Ponraj, Kari A. Gaither, Dilip Kumar Singh, et al.
Biochemical Pharmacology (2024) Vol. 230, pp. 116569-116569
Open Access
Efficacy of Ketamine Therapy in the Treatment of Refractory Major Depressive Disorder
Helena van Oers
Journal of Exploratory Research in Pharmacology (2023) Vol. 8, Iss. 4, pp. 295-298
Open Access
Page 1

Scroll to top